Context Therapeutics (NASDAQ:CNTX) Upgraded to “Buy” by Zacks Investment Research

Zacks Investment Research upgraded shares of Context Therapeutics (NASDAQ:CNTXGet Rating) from a hold rating to a buy rating in a report released on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $2.25 price objective on the stock.

According to Zacks, “Context Therapeutics Inc. is a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. Context Therapeutics Inc. is headquartered in Philadelphia, PA. “

Separately, HC Wainwright initiated coverage on shares of Context Therapeutics in a research note on Wednesday, February 2nd. They issued a buy rating and a $6.00 price objective for the company.

Shares of NASDAQ:CNTX opened at $2.05 on Wednesday. Context Therapeutics has a 52 week low of $1.27 and a 52 week high of $10.87. The firm has a fifty day simple moving average of $1.85 and a two-hundred day simple moving average of $2.62.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Context Therapeutics in the 4th quarter worth about $31,000. QCM Cayman Ltd. bought a new stake in shares of Context Therapeutics in the 4th quarter worth about $37,000. Vanguard Group Inc. lifted its holdings in shares of Context Therapeutics by 10.1% in the 1st quarter. Vanguard Group Inc. now owns 236,279 shares of the company’s stock worth $513,000 after acquiring an additional 21,600 shares during the last quarter. swisspartners Ltd. bought a new stake in shares of Context Therapeutics in the 4th quarter worth about $114,000. Finally, Virtu Financial LLC bought a new stake in shares of Context Therapeutics in the 4th quarter worth about $142,000. Hedge funds and other institutional investors own 28.51% of the company’s stock.

Context Therapeutics Company Profile (Get Rating)

Context Therapeutics Inc, a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers.

Read More

Get a free copy of the Zacks research report on Context Therapeutics (CNTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.